Aldeyra Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
28/04/2025 22:30
Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to show a fall in quarterly revenue when it reports results on April 30 (estimated) for the period ending March 31 2025 The Lexington Massachusetts-based company is expected to report revenue of $-800 thousand, according to the mean estimate from 5 analysts, based on LSEG data. ‚ÄčLSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 29 cents per share. The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $9.00‚Äč, above‚Äč its last closing price of $2.66. ‚Äč‚Äč‚Äč Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč
| QUARTER ENDING | STARMINESMARTESTIMATE¬ģ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.26 | -0.23 | -0.27 | Missed | -19.9 |
| Sep. 30 2024 | -0.26 | -0.25 | -0.25 | Met | -1.2 |
| Jun. 30 2024 | -0.14 | -0.14 | -0.28 | Missed | -97.5‚Äč |
| Mar. 31 2024 | -0.10 | -0.11 | -0.14 | Missed | -26.5 |
| ‚Äč‚ÄčDec. 31 2023 | -0.05 | -0.14 | -0.08 | Beat | 43 |
| Sep. 30 2023 | -0.22 | -0.24 | -0.14 | Beat | 41.3‚Äč |
| Jun. 30 2023 | -0.31 | -0.31 | -0.15 | Beat | 51.8 |
| Mar. 31 2023 | -0.29 | -0.29 | -0.27 | Beat | 7.4 |
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug